Press releases

• January 30, 2023 - Regulatory press releaseLecanemab receives priority review status in Japan
• January 27, 2023 - Regulatory press releaseEuropean Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease
• January 25, 2023 - Other press releaseInvitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET

Archive

Calendar

• February 3, 2023 08:00 CETFull year report January – December 2022
• April 27, 2023 08:00 CETInterim report January – March 2023
• June 1, 2023Annual General Meeting 2023
• July 12, 2023 08:00 CETHalf-Year report January – July 2023
• November 8, 2023 08:00 CETInterim report January – September 2023

Read more

Interim report Q4 2022

BioArctic AB will publish the company’s fourth quarter report for October – December 2022 on Friday, February 3, 2022, at 08:00 a.m. CET.

• Webcast

Read the invitation

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more